Please login to the form below

Not currently logged in
Email:
Password:

Nanobiotix strengthens US leadership team

Dr Mihail Obrocea and Noël Kurdi join the nanomedicine company

Nanobiotix Dr Mihail ObroceaFrench oncology specialist Nanobiotix has strengthened its US leadership team with the appointments of Dr Mihail Obrocea and Noël Kurdi.

Dr Obrocea (pictured right) joins Nanobiotix as head of US clinical development, bringing 20 years of clinical research leadership to the role.

Most recently, Dr Obrocea was AbbVie Biotherapeutics' project director and oncology clinical lead, overseeing a number of trials in oncology and hematology.

He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

Nanobiotix Noel KurdiMeanwhile, Kurdi (pictured left) becomes director of investor relations at Nanobiotix, moving from the Trout Group where she served as a senior associate.

Kurdi has previously worked in institutional equity sales and research at Brean Capital, and business development and investor relations at AIG Investments in New York.

7th October 2016

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...